Arcturus Therapeutics (ARCT) Reports Q3 Loss of $0.49

Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($0.49). Revenue for the quarter came in at $17.15 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c